MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MDXG • US6024961012

5.03 USD
-0.08 (-1.57%)
At close: Feb 5, 2026
5.0787 USD
+0.05 (+0.97%)
Pre-Market: 2/6/2026, 8:48:11 AM
Fundamental Rating

6

Overall MDXG gets a fundamental rating of 6 out of 10. We evaluated MDXG against 524 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, MDXG could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year MDXG was profitable.
  • In the past year MDXG had a positive cash flow from operations.
  • In multiple years MDXG reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • With an excellent Return On Assets value of 12.80%, MDXG belongs to the best of the industry, outperforming 94.47% of the companies in the same industry.
  • MDXG has a better Return On Equity (17.09%) than 95.04% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.15%, MDXG belongs to the best of the industry, outperforming 95.80% of the companies in the same industry.
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROIC 15.15%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • MDXG has a Profit Margin of 10.38%. This is amongst the best in the industry. MDXG outperforms 91.41% of its industry peers.
  • MDXG has a Operating Margin of 13.73%. This is amongst the best in the industry. MDXG outperforms 92.94% of its industry peers.
  • MDXG's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 81.99%, MDXG belongs to the top of the industry, outperforming 85.69% of the companies in the same industry.
  • MDXG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
  • MDXG has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MDXG has been increased compared to 5 years ago.
  • MDXG has a better debt/assets ratio than last year.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 7.86 indicates that MDXG is not in any danger for bankruptcy at the moment.
  • MDXG has a better Altman-Z score (7.86) than 79.39% of its industry peers.
  • The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.27, MDXG belongs to the best of the industry, outperforming 95.42% of the companies in the same industry.
  • A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
  • MDXG's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. MDXG is outperformed by 60.88% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Altman-Z 7.86
ROIC/WACC1.72
WACC8.79%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • MDXG has a Current Ratio of 4.41. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.41, MDXG perfoms like the industry average, outperforming 50.95% of the companies in the same industry.
  • A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
  • MDXG has a Quick ratio of 3.95. This is comparable to the rest of the industry: MDXG outperforms 49.05% of its industry peers.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 3.95
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
  • Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
  • MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%

3.2 Future

  • MDXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.54% yearly.
  • The Revenue is expected to grow by 14.49% on average over the next years. This is quite good.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.97, the valuation of MDXG can be described as correct.
  • MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.37% of the companies in the same industry.
  • MDXG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 20.13, which indicates a rather expensive current valuation of MDXG.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 93.32% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.20. MDXG is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 13.97
Fwd PE 20.13
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 97.71% of the companies in the same industry are more expensive than MDXG, based on the Enterprise Value to EBITDA ratio.
  • MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 98.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.15
EV/EBITDA 9.05
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MDXG may justify a higher PE ratio.
  • MDXG's earnings are expected to grow with 16.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MDXG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIMEDX GROUP INC

NASDAQ:MDXG (2/5/2026, 8:00:01 PM)

Premarket: 5.0787 +0.05 (+0.97%)

5.03

-0.08 (-1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)02-24
Inst Owners71.94%
Inst Owner Change-0.45%
Ins Owners1.79%
Ins Owner Change-0.11%
Market Cap744.94M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (147.32%)
Short Float %4.36%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-30.16%
EPS NQ rev (3m)-15.39%
EPS NY rev (1m)0%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.73%
Valuation
Industry RankSector Rank
PE 13.97
Fwd PE 20.13
P/S 1.89
P/FCF 11.15
P/OCF 10.98
P/B 3.12
P/tB 3.58
EV/EBITDA 9.05
EPS(TTM)0.36
EY7.16%
EPS(NY)0.25
Fwd EY4.97%
FCF(TTM)0.45
FCFY8.97%
OCF(TTM)0.46
OCFY9.11%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.29
PEG (5Y)N/A
Graham Number3.62
Profitability
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROCE 20.67%
ROIC 15.15%
ROICexc 33.2%
ROICexgc 44.66%
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
FCFM 16.98%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Debt/EBITDA 0.25
Cap/Depr 6.96%
Cap/Sales 0.26%
Interest Coverage 36.69
Cash Conversion 98.8%
Profit Quality 163.64%
Current Ratio 4.41
Quick Ratio 3.95
Altman-Z 7.86
F-Score6
WACC8.79%
ROIC/WACC1.72
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y18.36%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.


What is the profitability of MDXG stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.


What is the financial health of MIMEDX GROUP INC (MDXG) stock?

The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.


What is the earnings growth outlook for MIMEDX GROUP INC?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 47.72% in the next year.